WaveMan
WaveMan · Company
ITRMF · Iterum Therapeutics Plc
> Search tickers & screens ⌘K
LIVE
← All companies

ITRMF Iterum Therapeutics (ITRMF) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001659323
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
1
13F, latest reported quarter

Iterum Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Iterum Therapeutics plc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
1 fund bought in last quarter
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
3.3% of the float short (float per yahoo 2026-10-27) · 1000.0 days to cover · settled 2026-10-15
below 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ITRMF

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns ITRMF: institutional holders (13F)

13F holdings, latest reported quarter
BARCLAYS PLC
10,795 sh
$539
Cypress Capital Management LLC (WY)
66 sh
$3

Congress trades in ITRMF

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ITRMF planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 1 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ITRMF financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$19.5M
operating cash flow minus capex, 2024-10-01 to 2025-09-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.97x
TTM operating cash flow over LongTermDebt as filed 2025-09-30 (includes the current portion)
Return on equity
n/a
average equity is zero or negative
Return on assets
-111.3%
TTM net income over average of 2024-09-30 and 2025-09-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-177.2%
operating income (EBIT proxy) over average of 2024-09-30 and 2025-09-30 minus current liabilities
P/E, trailing
n/a
no close on file at or before the as-of date
Enterprise value
n/a
no close on file at or before the as-of date
FCF yield
n/a
no close on file at or before the as-of date
PEG, trailing
n/a
no close on file at or before the as-of date
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2024-122023-122022-122021-12
Revenuen/an/an/a$0
Operating income-$18.7M-$47.5M-$30.4M-$24.5M
Net income-$24.8M-$38.4M-$44.4M-$91.6M
EPS (diluted)-1.26-2.96-3.63-8.41
Operating cash flow-$26.8M-$39.3M-$18.5M-$15.8M
Cash$24.1M$6.1M$21.1M$27.4M
Long-term debt$31.2M$11.5M$10.1M$6.9M
SEC XBRL, fiscal years, as known on 2026-10-28

ITRMF Stock Sonar score 3/7 axes

Find similar shapesCompare

ITRMF ranks highest on risk and compliance (66th percentile) and financial health (53rd), and lowest on profitability (17th), among Pharma & Biotech peers.

Profitability
17
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-111.3% · 22 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-177.2% · 13 pct, sector of 576
Financial health
53
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.97x · 53 pct, sector of 371
Risk and compliance
66
Inputs
  • Short interest, % of float+3.3% · 66 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Growth, Insider conviction, Institutional and government, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies